TITLE:
Extranodal Locatio of Lymphoma: Presentation and Evolutionary in Senegalese Patients
AUTHORS:
Seynabou Fall, Mariéme Lolita Camara-Tall, El Hadj Daouda Niang, Khadim Sarr, Awa Ndiaye, Modou Moustapha Ciss, Aminata Dakono, Amy Thiam, Fatou Samba Diago Ndiaye
KEYWORDS:
Lymphoma, Extranodal Involvement, Advanced Stage, Senegal
JOURNAL NAME:
Open Journal of Blood Diseases,
Vol.13 No.1,
January
18,
2023
ABSTRACT: Introduction: The frequency of extranodal involvement in lymphoma is not rare, but
variously described by authors in Africa. The objective of our work is to
describe the profile of patients followed for lymphoma with extranodal
locations. Methods: We conducted a descriptive, retrospective and
analytic study at the clinical hematology department of Dalal Jamm Hospital,
from September 2016 to June 2022. We included patients with a diagnosis of lymphoma
immunohistochemistry, with extranodal involvement. The epidemiological,
diagnostic, prognostic and survival aspects were studied. Results: Fifty-two (52) patients with extranodal localizations of their lymphoma were
included. The mean age was 44.2 ± 17.6 years and the sex ratio was 1.2. The average time to
diagnostic was 9.4 ± 3.6 months. We found a performance status ≥ 2 in 65.4% and
at least one B symptom in 71.2% of cases. The extranodal manifestations were digestive
(19%), cutaneous (17.5%), pleuropulmonary (17.5%), bone marrow (4.8%), thyroid
(1.6%), parotid gland (1.6%) and breast (1.6%). Patients presented with Hodgkin’s
lymphoma (HL) in 19.2% of cases and non-Hodgkin’s lymphoma (NHL) in 80.8% of
cases. At the end of the extension checkup reviews, 61.5% were at an advanced
stage and prognostic indices were unfavorable in 32% of patients. Conventional chemotherapy was conducted in
63.5% of patients of which
24 had NHL and 9 had HL. Immuno-chemoterapy was used in 26.9% of patients (13
cases of NHL, 1 case of HL). During the follow-up, we noted only 29.7% of
complete remission. The median overall survival was 25.1 months [23.5 - 34.1 months] in HL group and 20.5 months [18.7 - 72.2 months] in NHL patients (p = 0.14). Conclusion: Our study shows that
extranodal involvements of lymphomas are various, encountered more during NHL.
In our practice, diagnosis is generally made at an advanced stage, with poor
response to treatment.